| Literature DB >> 31176270 |
Daniela Luvero1, Francesco Plotti2, Alessia Aloisia2, Roberto Montera2, Corrado Terranova2, Giuseppe Scaletta3, Salvatore Lopez2, Andrea Miranda2, Stella Capriglione2, Alessandra Gatti2, Roberto Angioli2.
Abstract
Ovarian cancer (OC) is the fifth most common cause of cancer death in women worldwide. Despite treatment options have continued to improve in recent years, the recurrence rate is still high; in fact around 80% of patients relapses within 18 months. Recently, the scientific landscape is agree in asserting that the ovarian cancer is not a single disease but the outcome of patients depends from the molecular and biological characterization of tumor tissue. In this scenario, molecular targeted therapy given alone or in combination with chemotherapy is showing significant results. We review the different options for the treatment of ovarian cancer recurrence, including the role of surgery, in order to try outlining a possible treatment algorithm evaluating the recent scientific literature and the most important trials.Entities:
Keywords: Chemotherapy; Ovarian cancer; Parp inhibitors; Recurrence
Mesh:
Substances:
Year: 2019 PMID: 31176270 DOI: 10.1016/j.critrevonc.2019.05.014
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312